Preclinical and clinical safety data includes [5] : No evidence of mutagenic activity, chromosomal aberrations, or micronucleus formation in genotoxicity studies 6-month chronic oral administration studies in rats showed no toxicological concerns 9-month studies in cynomolgus monkeys revealed general safety Six human clinical trials spanning 0.25 mg to 30 mg doses for up to 6 months No serious adverse events or withdrawals related to AOD9604 intake No anti-AOD9604 antibodies detected, indicating low immunogenic potential No changes in vital signs, physical examinations, electrocardiograms, or safety-related laboratory parameters Research Applications A Quick Review AOD9604 is a peptide compound that has shown potential in research related to lipid metabolism, energy balance, and tissue regeneration
All the above methods have been systematically validated
Other research explores cartilage support, maintaining joint matrix and reducing degradation markers in osteoarthritis models
This is not specific to tirzepatide or AOD 9604 but rather a consequence of rapid weight loss itself, known as telogen effluvium
Contact us today if you would like to learn more about our skinny shots and to see whether or not you are a good candidate for them.
Claims submitted outside the stated timeframe will not be eligible for review